Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03302767
Other study ID # IB2017-03
Secondary ID 2017-A01251-52
Status Completed
Phase N/A
First received
Last updated
Start date August 7, 2017
Est. completion date June 27, 2018

Study information

Verified date May 2021
Source Institut Bergonié
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This patient support system is designed to help patients regain their professional activity after their treatment. It's a 3-Axis neuropsycho-social synergy on 3 axes: - A weekly pluridisciplinary consultation in tandem (Social worker + Psychologist / Neuropsychologist) - Monthly information meetings and workshops (TIC'Onco reunions: collective information times and Cogit'Onco workshops: cognitive workshops - An information booklet "Prepare the work return" The aim of this research is to evaluate efficiency in term of quality of life improvement linked to work status, utility, feasibility and patients' satisfaction. The aim of this research is to evaluate efficiency in term of quality of life improvement linked to work status, utility, feasibility and patients' satisfaction.


Description:

Unmet need characterize in 4 points: - Cancer and survival: challenges for cancer patients who want to work while being treated - Cancer and career: Job instability for cancer patients - Difficulties and isolation of patients due to a lack of coordination between healthcare professionals and colleagues/management - Post-treatment cognitive troubles stress and hindered patient return to employment: chemo brain This research-action will propose and evaluate a concrete device: To maintain a professional activity with the support of CAP'Onco during treatment, to balance between quality of life, managing the "cancer event" and the psychosocial consequences for professional experience, to provide an early, durable and multimodal support to improve work keeping and anticipate return to employment


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date June 27, 2018
Est. primary completion date June 27, 2018
Accepts healthy volunteers No
Gender All
Age group 25 Years to 55 Years
Eligibility Inclusion Criteria: - Patients attending the Institut BergoniƩ - Informed Consent signed. - Patients affiliated to a French social - living in Gironde - Professional activity at the time of diagnosis - Treated for - breast cancer, Hodgkin's or non-Hodgkin's lymphoma (non-cerebral), testicular cancer - CURATIVE support - At any time during treatment (chemotherapy or radiotherapy, or immunotherapy) Exclusion Criteria: - Patient deprived of liberty or subject to a legal protection measure - History of cancers - Cerebral pathology and / or brain metastasis

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Psychological and Social Consultation
Psychological and Social Consultation at Baseline, during the study and at the end of follow-up

Locations

Country Name City State
France Institut Bergonié Bordeaux

Sponsors (1)

Lead Sponsor Collaborator
Institut Bergonié

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Quality of Life : EORTC QLQ-C30 Scores Standardised QLQ-C30 scoring according to EORTC scoring manual (Fayers et al. EORTC QLQ-C30 scoring manual. 2001).
15 dimensions are presented below. Each dimension is a standardised score ranges from 0 to 100. A low score corresponds to a low functional level, an absence of symptoms or a low level of QoL/ overall health and, conversely, so that a high score corresponds to a high functional level, a high presence of symptoms or a high level of QoL/overall health.
At baseline and 5 months
Primary Cognitive Complaints : FACT Cog Scale Scores Cognitive complaints were evaluated by using the french Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) scale version 3
Assessed using median total score (range 0-132) and median scores of these 4 dimensions :
Perceived Cognitive Impairment (range 0-72)
Impact on quality of life (range 0-16)
Comments from others (range 0-16)
Perceived Cognitive Skills (range 0-28) Higher scores indicate better cognitive functioning.
At baseline and 5 months
Primary Professional Recovery Scale Scores Professional recovery was evaluated by using the Scale of motivation to Professional recovery.
This scale was constructed for the needs of this exploratory research and has for vocation a later validation.
It includes 62 questions and was assessed using median scores of these 7 dimensions :
Work and administrative process (0-100)
Positioning in relation to the job-post-mission (0-100)
Emotion and work (0-100)
Labour relations (0-100)
Work and physical/intellectual conditions (0-100)
Privacy and work (0-100)
Return to work (0-20) Higher scores represent better outcomes
At baseline and 5 months
Secondary Tiredness : Piper MFI-20 Scale Scores Tiredness was evaluated by using the Piper Multidimensional Fatigue Inventory (MFI-20) revised scale
Assessed using median total score (range 0-10) and median scores of these 4 tiredness dimensions :
Behavioural
Emotional
Sensory
Cognitive-mood Each dimension has range 0-10 with following interpretation: higher scores indicate greater severity of fatigue
At baseline and 5 months
Secondary Anxio-depressive Troubles : HAD Scale Scores Anxio-depressive troubles were evaluated by using the Hospital Anxiety and Depression (HAD) scale.
Assessed using median scores of these 2 dimensions :
Anxiety
Depression Each dimension has range 0-21 with following interpretation: higher scores represent worse outcomes (0-7 normal; 8-10 mild; 11-14 moderate; 15-21 severe)
At baseline and 5 months
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases